Elanco Animal Health Incorporated ELAN
Composite 38/100; the shares have moved about 50% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 22/100 — a strong mark against it.
Momentum ranks 61/100 — a slight point in its favour.
Growth ranks 22/100 — a strong mark against it. Quality ranks 28/100 — a moderate mark against it. Balance-sheet strength ranks 40/100 — a slight mark against it.
What the company does Elanco Animal Health innovates, develops, manufactures, and markets animal health products for pets and farm animals worldwide. Its portfolio includes parasiticides, vaccines, and therapeutics for pets under brands like Seresto and Credelio Family, and farm animal solutions such as Rumensin and Baytril.
Key financials Elanco reports gross margins of 55.1% but net margins of -5.0%, with revenue growth of 14.9% but EPS declining -15.4%. ROE is -3.8%, ROA 1.5%, and ROCE 0.6%. Debt/Equity stands at 0.66, net debt/EBITDA at 3.99, and interest coverage is 0.27.
Stock health The stock shows strong momentum with 12-month returns of 83.88%, though it is -4.55% below its 52-week high. RSI(14) is 64.30, indicating elevated but not extreme buying pressure. The SidraVestia Overall Score is 42.2, reflecting poor quality but positive momentum.
Price vs fair value ELAN trades at a **PREMIUM of 33.70%** to our fair-value estimate of 17.54 and a **discount of 13.65%** to the analyst 12-month target of 30.07. - UBS views Elanco as best-positioned into Q2 among animal health stocks (MT Newswires) - Simply Wall St. highlights potential upside from new tick-data for Credelio Quattro - Simply Wall St. also notes ELAN may be below fair value despite a 108% return test - Zacks anticipates earnings growth in upcoming results
Looking forward Forward P/E is 22.62, with EV/EBITDA at 21.89. Analysts (14.0) see a 12-month target of 30.07, implying ~14% upside from the current price. However, weak profitability metrics (net margin -5.0%) and high leverage (net debt/EBITDA 3.99) remain key risks.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.